# Semaglutide

Semaglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). The SELECT trial demonstrated a 20 percent reduction in major adverse cardiovascular events in adults with obesity and established cardiovascular disease without diabetes. Longevity-relevant mechanisms include sustained weight loss, improved insulin sensitivity, lower inflammation, and possible cognitive and renal protection. Off-label use solely for lifespan extension in healthy adults is investigational and not endorsed.

## Sources

- Lincoff AM, Brown-Frandsen K, Colhoun HM et al.. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial). New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2307563

---

_Canonical: https://longevity-austria.com/en/glossary/semaglutide · Part of Longevity Cities · Updated 2026-01-15_